BPG is committed to discovery and dissemination of knowledge
Clinical Trials Study
©The Author(s) 2026.
World J Gastroenterol. Feb 7, 2026; 32(5): 113505
Published online Feb 7, 2026. doi: 10.3748/wjg.v32.i5.113505
Figure 3
Figure 3 Kaplan-Meier curves for the time to first onset of anti-drug antibodies and drug survival based on initial infliximab clearance. A: Effect of clearance on time to development of anti-drug antibodies. Black line: Low clearance, orange line: Medium clearance and green line: Fast clearance; B: Effect of use of immunomodulators on time to development of antidrug antibodies. Orange line: Some or no immunomodulator used, black line: No immunomodulator used; C: Effect of clearance on drug survival. Black line: Low clearance, orange line: Medium clearance, green line: Fast clearance.


Write to the Help Desk